Breaking News

Selexis Inks Commercial Cell Line License Agreement with ImmuNext

Relates to anti-CD40L antibody being developed for treatment of chronic autoimmune disorders

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Selexis has signed a commercial license agreement that provides ImmuNext with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform to advance the development of ImmuNext’s anti-CD40 ligand (CD40L) antibody. ImmuNext is developing this antibody for treatment of chronic autoimmune disorders such as lupus, inflammatory bowel disease and multiple sclerosis. CD40L (also called CD154) is a highly validated, superlative therapeutic target in autoimmunity and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters